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Glioblastoma multiforme is characterised by invasive growth and frequent recurrence. Here, we have analysed chromosomal changes
in comparison to tumour cell aggressiveness and chemosensitivity of three cell lines established from a primary tumour and
consecutive recurrences (BTL1 to BTL3) of a long-term surviving glioblastoma patient together with paraffin-embedded materials of
five further cases with recurrent disease. Following surgery, the BTL patient progressed under irradiation/ lomustine but responded to
temozolomide after re-operation to temozolomide. The primary tumour -derived BTL1 cells showed chromosomal imbalances
typical of highly aggressive glioblastomas. Interestingly, BTL2 cells established from the first recurrence developed under therapy
showed signs of enhanced chromosomal instability. In contrast, BTL3 cells from the second recurrence resembled a less aggressive
subclone of the primary tumour. Although BTL2 cells exhibited a highly aggressive phenotype, BTL3 cells were characterised by
reduced proliferative and migratory potential. Despite persistent methylation of the O
6-methylguanine-DNA methyltransferase
promoter, BTL3 cells exhibited the highest temozolomide sensitivity. A comparable situation was found in two out of five
glioblastoma patients, both characterised by enhanced survival time, who also relapsed after surgery/chemotherapy with less
aggressive recurrences. Taken together, our data suggest that pretreated glioblastoma patients may relapse with highly
chemosensitive tumours confirming the feasibility of temozolomide treatment even in case of repeated recurrence.
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Malignant transformation and progression is thought to be based
on the stepwise accumulation of genetic changes that confer
growth and survival advantages to (pre)malignant cells. Conse-
quently, solid tumours at diagnosis are generally characterised by
complex karyotypic alterations and an increasing number of
chromosomal aberrations have been shown to be associated with
tumour development and progression (reviewed by Albertson et al
(2003)). This clonal evolution in combination with chromosomal
instability may result in the development of variant subclones
within one tumour harbouring different sets of genetic changes.
Human malignant gliomas represent the most common primary
malignant brain tumour comprising astrocytomas, oligodendro-
gliomas, ependymomas, and tumours of the coroid plexus. The by
far most frequent histological entity is glioblastoma (astrocytoma
WHO grade IV), typically composed of different cell types
displaying a wide spectrum of heterogeneity regarding morpho-
logy (referred to by the term ‘multiforme’), biological aggressive-
ness, invasive potential, as well as treatment sensitivity (Mao and
Hamoudi, 2000; Zhu and Parada, 2002). Glioblastomas arise either
de novo without evidence of an antecedent lesion (primary
glioblastoma) or through an anaplastic progression from a
lower-grade astrocytoma (secondary glioblastoma). Genetic stu-
dies revealed that there are different distinct pathways involved in
the development of these lesions. Although in primary glioblas-
toma loss of the tumour suppressors p16/Cdkn2/Ink4 and PTEN as
well as amplifications in EGFR and HDM2 are frequent, secondary
glioblastomas lose p53 already at the stage of low-grade
astrocytoma (Mao and Hamoudi, 2000; Zhu and Parada, 2002).
With respect to chromosomal aberrations deletions of 1p, 9p,
10, 13q, 17p, 19q, and 22q, and gains of chromosome 7 ( Liu et al,
1997; Rasheed et al, 1997; Duerr et al, 1998; Smith and Jenkins,
2000) are the most common in gliomas. Several genes have been
identified to be associated with tumorigenesis and anaplastic
progression of glioblastoma subgroups including, besides the
already mentioned p16/Cdkn2/Ink4, EGFR, PTEN, p53, and HDM2
also for example cdk4, cyclin D1, PDGFRa, k-ras, N-myc, gli,
c-myc, and myb (Mao and Hamoudi, 2000; Zhu and Parada, 2002).
Despite intensive research regarding the genetics and biology,
the prognosis of glioblastoma patients is still poor. Even in case of
maximal therapy, median survival of glioblastoma patients remains
low and ranges between 10 and 12 months, only (Scott et al, 1998).
Thus, a more profound knowledge of the molecular background and
cell biological behaviour of this cancer is inevitable to develop
appropriate treatment strategies (Buckner, 2003).
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sThe current standard of care for patients with high-grade
malignant glioma used to be resection followed by radiotherapy
(RT). However, the use of adjuvant and/or concomitant chemo-
therapy and the standard of care at first relapse are still under
debate (van den Bent et al, 2006). Chemotherapeutic treatment
success in brain tumours is mainly limited by the blood–brain
barrier and the expression of chemoresistance-related proteins like
P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), and
major vault protein (MVP) also known as lung resistance protein
(LRP) (Berger et al, 2001; Bredel, 2001; Spiegl-Kreinecker et al,
2002). Based on their ability to circumvent the blood–brain
barrier, alkylating agents represent the gold standard in the
treatment of malignant gliomas. Besides nitrosoureas, temozolo-
mide is the most promising drug in the current treatment of
patients with malignant gliomas. Temozolomide has demonstrated
a good tissue distribution, including penetration of the blood–
brain barrier and the cerebrospinal fluid (DeAngelis, 2003).
Recently, a significant survival benefit for glioblastoma patients
treated with temozolomide combined with RT was shown (Stupp
et al, 2005). However, protection against the toxic effect of
alkylating agents might rely on the activity of O
6-methylguanine-
DNA methyltransferase (MGMT) (Harris and Margison, 1993) a
key enzyme in the DNA repair network.
In this study, we present, to the best of our knowledge, a unique
glioblastoma cell model consisting of one primary tumour- and
two recurrences-derived permanent cell lines from a single patient
(BTL). Chromosomal changes as well as cell-biological behaviour
and treatment responsiveness were compared to the respective
clinical observations and to five further patients with recurrent
glioblastoma (GL1–5). We demonstrate that even in case of
repeated recurrence and heavy pretreatment with chemotherapy –
believed to be often associated with acquired chemotherapy
resistance (Bredel, 2001) – glioblastoma patients may relapse with
less aggressive tumours highly responsive to chemotherapy.
MATERIALS AND METHODS
Patient characteristics and clinical course of disease
BTL cells were derived from a 51-year-old woman who underwent
surgery of glioblastoma within the right frontal lobe at the
Department of Neurosurgery, Wagner-Jauregg-Hospital, Linz,
Austria. The clinical course of disease and treatment is depicted
in Table 1. Post–operative before RT, the patient received one
cycle lomustine (CCNU) (100mgm
 2 body surface area). Radio-
therapy started 6 weeks after surgery, but had to be ceased
incomplete (4000cgy) because of tumour progression. The patient
was re-operated 3 months after resection of the primary tumour
and afterwards received seven cycles temozolomide (200mgday
 1
1–5 every 28 days). After the third cycle, reduction of the tumour
bulk was observed by magnetic resonance imaging (MRI), which
was confirmed as partial regression after the seventh cycle.
Tumour regression was accompanied by continual improvement
of performance status. After 8 months, a second recurrence,
indicated by sudden worsening of performance status, was
confirmed by MRI. Consequently, the patient underwent re-
surgery 17.5 months after the first relapse but refused further
chemotherapy. After 3 months, MRI confirmed tumour progres-
sion leading to disease-related death 27 months after initial
diagnosis.
Formalin-fixed, paraffin-embedded tissues of primary tumours
and recurrences derived from additional five glioblastoma patients
(GL1–5) with recurrent disease were obtained from the Institute of
Pathology, Wagner Jauregg Hospital, Linz. Therapy response and
overall survival times are depicted in Table 3. All patients gave
informed consent.
Establishment of tumour cell cultures
Primary cell cultures were established from all three surgery
specimens (BTL1, BTL2, and BTL3) and were used at passage
numbers 5–15 for analysis. Patches from non-necrotic parts of the
tumour were obtained during surgery, minced mechanically and
transferred into culture flasks, containing growth medium (RPMI
1640, 20% fetal calf serum (FCS), 1% glutamine, 1% penicillin/
streptomycine; PAA Laboratories, Linz, Austria). After the third
passage, cells were grown in growth medium with 7% FCS and 1%
glutamine and without antibiotics. Three to five culture flasks were
set up from each surgery specimen. Cell cultures were then pooled
during the first passages. All cell cultures were periodically
checked for Mycoplasma contamination (Mycoplasma Stain Kit;
Sigma, St Louis, MO, USA).
Cytogenetic analyses
Microdissection of paraffin-embedded materials was carried
out using the Leica AS LMD Laser Microdissection System
(Cambridge, UK). Preparation of genomic DNA was performed
as described previously (Pirker et al, 2004). Comparative genomic
Table 1 Course of disease of the BTL patient
Month 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
OP CCNU RT OP 2.Temo 3.Temo 4.Temo 5.Temo 6.Temo 7.Temo Stable MRI MRI Death
(BTL1
a) 1cycle (BTL2
a) MRI MRI Disease prog. OP prog.
1.Temo Regress Regress (BTL3
a)
aEstablishment of the indicated BTL cell cultures from the respective surgery (OP) specimens. CCNU, lomustine; RT, radiotherapy; Temo, temozolomide; prog, tumor
progression.
Table 2 Chemosensitivity of the investigated cell lines
Cytotoxicity (IC50)
a
Cell line TMZ (lM) BCNU (lM) DOX (nM) L-DOX (nM) DM (ngml
 1) VP-16 (lM) CDDP (lM)B L E O ( lgml
 1)
BTL-1 1225.0 141.10 200.00 83.30 150.00 430.00 410.00 415.00
BTL-2 895.0 211.80 99.20 116.10 54.60 430.00 410.00 415.00
BTL-3 367.6 287.00 39.30 9.30 82.20 430.00 410.00 415.00
aData are expressed as IC50 values (means of three experiments performed in triplicate) of the tested drugs (temozolomide, TMZ, carmustine, BCNU; doxorubicin, DOX;
liposomal doxorubicin, L-DOX; daunomycin, DM; etoposide, VP-16; cisplatin, CDDP; bleomycin, BLEO).
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shybridisation (CGH), fluorescence in situ hybridisation (FISH) and
CDD banding were performed as described previously (Pirker
et al, 2004). For DNA amplification, linker–adapter PCR was used
as described (Pirker et al, 2004). For the detection of the EGFR
locus, the BAC clone RP11-339F13 supplied by Pieter De Jong
(Oakland, CA, USA) was used.
Growth curves
A total of 5 10
4cellswell
 1 were seeded into six-well plates. Every
48h cells were collected and counted in 0.2% trypan blue solution,
whereas medium changes were performed for the remaining
samples.
Scratch assay
Cells (2 10
5well
 1) were plated in a six-well plate. When the cells
had reached about 90% confluence, the monolayer was wounded
by setting an ‘X’-shaped scratch with a sterile plastic tip. Several
areas of the scratch were documented by photomicrographs and
followed for up to 44h. The width of the gap was measured at
several time points with a Leica TE100 microscope equipped with a
CCD camera (Cambridge, UK) and the gap width was measured
using Metamorph 6.1 software (Universal Imaging Corp., Biocom-
pare).
Bisulphite modification and MSP
Methylation-specific PCR (MSP) exploits the effect of sodium
bisulphite on DNA, which efficiently converts unmethylated
cytosine to uracil but which leaves methylated cytosine unchanged.
DNA from cultured cells was extracted with QIAmp DNA Blood
Mini Kit (Qiagen, Valencia, CA, USA) and 1mg of genomic DNA
was denatured with NaOH (3 M). Following denaturation, 10mM
hydrochinone (Sigma) and 3 M sodium-bisulphite (Sigma) were
added and DNA modification was performed at 501C for 16h. DNA
samples were then purified with the Wizard DNA purification
resin (Promega, Mannheim, Germany) followed by ethanol
precipitation. Methylation-specific PCR was performed with
primers specific for either methylated or modified unmethylated
DNA, as described previously (Esteller et al, 1999). For PCR a 25ml
mix consisting of DNA, specific primers and HotStarTaqMaster-
Mix (1.25U HotStarTaq DNA Polymerase; 1 PCR buffer; 100mM
of each dNTP; Qiagen) was prepared and amplification was carried
out in the iCycler Thermal Cycler (BioRad, Hercules, CA, USA)
starting with an initial activation step at 951C for 15min. Thirty-
five cycles were performed with an annealing temperature of 661C.
DNA from melanoma metastasis primary cell cultures served as
control for methylated as well as unmethylated MGMT promoter.
A total of 10ml of each PCR reaction were loaded onto a 6%
polyacrylamide gel and ethidium bromide-stained gels were
visualised under UV illumination (ChemiDoc; BioRad). Expression
levels were quantified by Quantity One Quantitation software
(BioRad) and calculated relatively to the indicated controls.
RT–PCR
mRNA expression of the chemoresistance-related proteins MGMT,
P-gp, MVP, and MRP1 was determined by RT–PCR analysis. Total
cellular RNA was extracted and RT–PCR performed with One Step
RT–PCR Kit (Qiagen) using oligonucleotide primer sets specific
for MGMT (sense 50-CCTGGCTGAATGCCTATTTC-30; antisense
50-CAGCTTCCATAACACCTGTCT-30; product size: 116bp), P-gp
(sense 50-CCCATCATTGCAATAGCAGG-30; antisense 50-GTTC
AAACTTCTGCTCCTGA-30; 170bp), MVP (sense 50-TTCTGGAT
TTGGTGGACGC-30; antisense 50-MVP antisense 50-ACTT
CTCTCCCTTGACCA-30; 284bp) and MRP1 (sense 50-GGACCTG
GACTTCGTTCTCA-30; MRP1 antisense 50-CGTCCAGACTTCTT
CATCCG-30; 291bp). GAPDH was amplified (358bp) as described
in (Berger et al, 2000) as a housekeeping gene. For semiquanti-
tative evaluation, 30 cycles were chosen for MGMT, P-gp, MVP,
and MRP1 and 22 cycles for GAPDH. Amplification was performed
in a thermal cycler (iCycler; Bio-Rad) under the following cycle
conditions: 941C for 30s; 561C for 40s; 721C for 40s. Amplification
products were separated by acrylamide gel electrophoresis, stained
with ethidium bromide and quantified by scanning densitometry
(Chemi Doc, Quantity One Quantitation software, Bio-Rad,
Hercules, CA, USA). Expression levels (arbitrary units) were
calculated relatively to GAPDH mRNA amplified concomitantly.
Western blot
Protein expression was determined by immunoblot analysis. Total
protein extracts (determination of MGMT and MVP) as well as
preparation of crude membrane extracts (P-gp, MRP1) were
prepared as described previously (Berger et al, 1997; Berger et al,
2000) and protein concentrations measured with BCA Protein
Assay (Pierce, Rockford, IL, USA). Proteins were separated by
SDS–PAGE and transferred onto nitrocellulose membranes
(Hybond ECL, Amersham, Aylesbury, UK). Blots were probed
with monoclonal antibodies against MGMT (Dako, Glostrup,
Denmark), MVP (Transduction Laboratories, Lexington, KY,
USA), P-gp (C219; Centocor, Malvern, PA, USA) and MRP1
(MRPr1; Alexis Biochemicals, San Diego, CA, USA). Visualisation
and quantification were performed using the ChemiDoc System
(BioRad, Hercules, CA, USA). In previous studies, multiple
glioblastoma cell lines established in our laboratory were
extensively characterised for their expression of drug resistance
genes (Berger et al, 2001; Bredel, 2001; Spiegl-Kreinecker et al,
2002). Respective protein extracts of the following cell lines have
been used as positive controls in Western blot analysis: for MGMT
GL80, for MVP GL54, for MRP1 GL52 and for P-gp YT-BO.
Chemosensitivity testing
The impact of the investigated drugs on cell proliferation and
viability was tested by establishing whole dose–response curves
using an MTT-based survival assay (EZ4U, Easy-for-you,
Biomedica, Vienna, Austria). Cells in logarithmic growth phase
were seeded in triplicates into three 96-well plates (3 or
1.5 10
3100mlwell
 1) and incubated for 24h at 371C. All drugs
were applicated for 72h or 5 days continuous exposure. The
surviving proportions of cells as compared to the untreated
controls were determined using EZ4U according to the instruc-
tions of the manufacturer. Experiments were repeated three times
and IC50 values were calculated from whole dose–response curves.
Additionally, the impact of temozolomide on
3H-thymidine
incorporation was determined in BTL cells. Cells (4 10
3 per
Table 3 Chromosomal changes, therapy sensitivity, and overall survival
in glioblastoma primary tumours (PT) and corresponding recurrences (Rec)
Number of changes
a Response to therapy
b
OS
Case PT Rec 1 Rec 2 PT Rec 1 Rec 2 Months
GL1 9/1 12.5/2 18/3 — — — 21
GL2 9.3/3 12/5 — — 17,5
GL3 3.7/3 17.5/2 — — 14.5
GL4 24/1 n.a.
c 14/1 + n.t.
e n.t. 39
GL5 5.5/2 4.7/3 — + 26 a.
d
BTL n.a. n.a. n.a. — + n.t. 27
aChromosomal aberrations were determined by CGH and chromosome arms with
significant changes counted. Data are given as mean changes/microdissected areas
analysed.
bTherapy of TMZ or CCNU was scored in vivo as + when the patient
showed partial response or stable disease.
cNot analysed;
dAlive;
eNo therapy.
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s100mlwell
 1) were seeded into a 96-well plate and after 24h
exposed for 48h to 50–1500mM temozolomide. After the exposure
culture medium was replaced for 1h by a 2nM
3H-thymidine
solution (diluted in full culture medium, radioactivity:
25CimM
 1). Afterwards cells were washed three times with PBS,
cell lysates prepared and radioactivity was determined as described
(Berger et al, 1994). Experiments were carried out in triplicates and
results (means of two experiments) are expressed relatively to the
untreated controls set arbitrarily as 1.
In order to determine the cytotoxic activity of temozolomide,
Hoechst 33258/propidium iodide (PI) co-staining (both from
Sigma) to determine the number of viable and apoptotic/dead
cells was performed as described (Grusch et al, 2001). Cells in
logarithmic growth phase were seeded in triplicates into 96-well
plates (1 10
3 per 100mlwell
 1) and incubated for 24h at 371C.
Temozolomide was applicated for 5 days of continuous exposure.
Hoechst 33258 and PI were added directly to the culture medium
to final concentrations of 5 and 2mgml
 1, respectively. After an
incubation period of 1h at 371C the cells were examined on a Zeiss
Axiovert 35 fluorescence microscope with DAPI filters, and viable
(Hoechst-positive, PI-negative) and dead (Hoechst-positive, PI-
positive)/apoptotic (Hoechst-positive with condensed/fragmented
chromatin, PI-negative) cells were counted.
Drugs
Temozolomide and liposomal doxorubicin (L-DOX) were kindly
provided by AESCA Pharma (Traiskirchen, Austria). All other
drugs used were obtained from Sigma (St Louis, MO, USA).
Cytotoxic effects were analysed for daunomycin (9–180nM),
etoposide (VP16; 0.5–25mM), cisplatin (CDDP; 0.25–5mM),
doxorubicin (DOX; 10–150nM), L-DOX (10–150nM), bleomycin
(BLEO 1–100mUml
 1), carmustine (BCNU; 50–600mM), and
temozolomide (TMZ 100–1500mM). Drugs were dissolved in
physiological saline (DM, DOX), DMSO (VP16, TMZ), ethanol
(BCNU), and aqua bidest (BLEO, CDDP). L-DOX was provided as
sterile solution ready for use.
RESULTS
Cytogenetic analyses of BTL1-3 cells show changes typical
for glioblastoma multiforme
Three cell lines termed BTL1, BTL2, and BTL3 were established
from consecutive surgeries of a primary tumour and two
recurrences of a long-term surviving glioblastoma patient. The
respective course of disease, therapies, and the time points of
surgery are summarised in Table 1. Chromosomal changes in
the cell lines were analysed by CGH and classical cytogenetics.
Figure 1A–C present the CGH profiles of all three cell cultures.
The primary tumour-derived cell line BTL1 contained chromo-
somal changes typical for glioblastoma, for example, gain of
chromosome 7, loss of 9p, as well as loss of chromosome 10
(indicated by arrows in Figure 1A). A respective CGH metaphase
for BTL1 is given in Figure 2A. BTL2 cells, derived from the first
recurrence progressing during RT and chemotherapy, showed
numerous additional chromosomal changes as compared to BTL1
(asterisks in Figure 1B). Some of these aberrations (losses at
chromosomes 2, 6q, and 12q) reached only borderline significance
in BTL1 and were distinctly more pronounced in BTL2, whereas
other changes (gains at chromosomes 14, 17p, and 20, losses at
chromosomes 17q and 18) were completely new in BTL2. This
increase in genomic aberrations reflects a high degree of
chromosomal instability of BTL2 cells. Unexpectedly, CGH
analysis of BTL3 cells, derived from a second recurrence resected
15 months later, revealed a less aberrant chromosomal pattern
with loss of most changes present in BTL2 (a remaining change is
shown as asterisk in Figure 1C) and only very few new changes
(crosses in Figure 1C). Interestingly, chromosome 7 amplifications
present in BTL1 and BTL2 were completely lost in BTL3 cells.
Conventional cytogenetics (Figure 2D–F), as well as FISH analysis
of BTL cells (Figure 2B and C), widely confirmed the results
obtained by CGH. The CDD banding of tumour metaphase
chromosomes revealed the existence of at least two different
subclones in BTL1 cells. The predominant subclone showed a
highly aberrant, nearly tetraploid karyotype with additional copies
of chromosome 7 (Figure 2D), whereas the second subclone
displayed a less aberrant, nearly diploid karyotype with only two
copies of chromosome 7 (Figure 2E). FISH analysis with
chromosome paint for chromosome 7 and a specific BAC clone
against the EGFR gene locus confirmed these results (Figure 2B).
The highly aberrant and instable karyotype of BTL2 cells was
confirmed by CDD banding and FISH (data not shown). CDD
banding as well as FISH data for BTL3 revealed a mainly triploid
karyotype and, corresponding with CGH results, three copies of
chromosome 7 (Figure 2C and F).
CGH analyses of glioblastoma multiforme primary
tumours and recurrences
In addition to the BTL cell model, paraffin-derived materials from
the primary tumour and one or two recurrences of five further
glioblastoma patients were available for analysis. The numbers of
chromosomal changes in these tumour samples were compared to
chemotherapy responses and overall survival (Table 3). Tumours
of patients GL1, GL2, and GL3 showed increased chromosomal
aberrations during disease progression, therapy resistance, and
relatively short overall survival (mean of 17.67 months). In
contrast, patients GL4 and GL5 displayed distinctly reduced
chromosomal instability and in case of GL5 therapy sensitivity in
recurrent tumour thus resembling the in vitro BTL cell model.
Interestingly, all three respective patients showed remarkable long
overall survival (mean of 33 months, patient GL5 still alive at 26
months) although GL4 had refused chemotherapy at recurrence.
These observations again indicate that chemosensitive glioblasto-
ma patients may relapse with a less aggressive tumour subclone
corresponding to long-term patient survival.
Growth and migration potential
In parallel to the chromosomal changes, several determinants of
tumour cell malignancy were analysed in BTL cells. In vitro cell
growth potentials were analysed by establishment of growth curves
(Figure 3). Whereas the primary tumour -derived BTL1 cells were
relatively slow-growing, BTL2 cells showed significantly increased
growth potential especially at enhanced cell density. In contrast,
BTL3 cells displayed reduced cell proliferation as compared to
BTL2 and trended to enter plateau stage at higher density.
Additional to cell growth, the migratory potential of all BTL cell
lines was assessed by monolayer scratch assays. Figure 4A shows
photomicrographs of representative scratches in BTL cell mono-
layers immediately after wounding and following 20h of incuba-
tion. Figure 4B summarises graphically the results from several
analysed time points. Although BTL3 cells had completely closed
the wound already within 20h, for both BTL1 and BTL3 the scratch
was still visible even after 44h of incubation. At these late time
points, the parental BTL1 cell line exhibited a slightly higher
migratory potential as compared to the second recurrence-derived
BTL3 cells that were unable to close the wound even by 72h (data
not shown).
Sensitivity against chemotherapeutic interventions
Chemosensitivity of BTL cell lines against several anticancer agents
was established by MTT-based survival assays (Table 2). Using a
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sBTL 1
BTL 2 B
A
+
+
C BTL3
1–21 0–2.5 0–2.5 0–2.5 0–2.5 0–2.5
0–2.5 0–2.5 0–2.5 0–2.5 0–2.5 0–2.5 0–2.5
0–2.5 0–2.5 0–2.5 0–2.5 0–2.5 0–2.5
0–2.5 0–2.5 0–2.5 0–2.5 0–2.5 0–2.5
0–2.5 0–2.5 0–2.5 0–2.5 0–2.5
0–2.5 0–2.5 0–2.5 0–2.5 0–2.5 0–2.5 0–2.5
0–2.5 0–2.5 0–2.5 0–2.5 0–2.5 0–2.5
0–2.5 0–2.5 0–2.5 0–2.5 0–2.5 0–2.5
0–2.5 0–2.5 0–2.5 0–2.5 0–2.5
0–2.5 0–2.5 0–2.5 0–2.5 0–2.5 0–2.5 0–2.5
0–2.5 0–2.5 0–2.5 0–2.5 0–2.5 0–2.5
0–2.5 0–2.5 0–2.5 0–2.5 0–2.5 0–2.5
2–18 3–21 4–19 5–20
12–18 11–20 10–21 9–21 7–22 8–22 6–18
13–22
19–22
1–21
6–21
2–17 3–17 4–20 5–21
12–22
13–17 14–20 15–20 16–22 17–22 18–21
Y–11 X–11 22–22 21–20 19–20
1–17 2–21 3–23 4–21 5–21
12–22 11–24 10–23 9–22 8–23 7–24 6–19
13–23 14–23 15–24 16–24 17–22 18–23
19–23 20–23 21–24 22–23 X–11 Y–12
20–20
11–21 10–21 9–21 8–20 7–17
20–22 21–21 22–21 X–11 Y–11
14–21 15–21 16–21 17–22 18–21
Figure 1 CGH analysis profiles (for interpretation see Pirker et al, 2003) of (A) primary tumour-derived BTL1, (B) first recurrence-derived BTL2, and (C)
second recurrence-derived BTL3 cells. Arrows in (A) indicate typical changes for glioblastoma multiforme. Asterisks in (B) indicate additional chromosomal
aberrations in BTL2 as compared to BTL1. In (C) the asterisk indicates an aberration present also in BTL2 but not BTL1. Crosses in (C) represent changes
unique to BTL3.
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s72h drug exposure, an increasing sensitivity against temozolomide
within the BTL cell model was detected by the vitality assay. Thus,
BTL3 cells, derived from a recurrence 9 months after successful
temozolomide treatment (compare Table 1), exhibited the highest
temozolomide sensitivity. With respect to a 72h continuous drug
exposure, activity of the second alkylating agent BCNU revealed an
opposite resistance pattern with the lowest IC50 value in BTL1 cells.
Resembling temozolomide, also, the sensitivity against anthracy-
clines tended to be enhanced in the recurrence-derived sublines
with the strongest differences observed in case of doxorubicin.
As characteristic of glioblastoma cells (Bredel, 2001), all BTL
sublines were resistant against VP-16, bleomycin, and CDDP.
Extending the exposure time in the case of temozolomide to 5 days
confirmed the lowest temozolomide sensitivity for the primary
tumour -derived cell line BTL1 (IC50: 605.8mM), whereas at that
exposure time BTL2 cells showed the highest treatment response
(IC50: 158.3mM). The higher temozolomide sensitivity of BTL2 cells
with increasing exposure time might be explained by the enhanced
proliferation of this cell line at higher densities (compare Figure 3).
To test this hypothesis, we analysed the impact of a 48h
temozolomide exposure on DNA synthesis of BTL cells seeded at
enhanced density by
3H-thymidine incorporation (Figure 5A).
Indeed, temozolomide treatment reduced DNA synthesis of BTL2
cells significantly stronger as compared with BTL3, whereas BTL1
cells showed the weakest response. In order to explain the higher
temozolomide sensitivity of BTL3 cells in the 72h survival assay
(compare Table 2), we additionally analysed the cytotoxicity of
temozolomide against BTL cells at a 5-days exposure time
(Figure 5B). Both recurrence-derived cell lines demonstrated a
significantly enhanced percentage of apoptotic/dead cells as
compared to parental BTL1 cells with BTL3 showing the highest
response to the cytotoxic impact of temozolomide.
Gene expression of chemoresistance-related proteins
Expressions of the DNA repair enzyme MGMT as well as the
chemotherapy resistance markers P-gp, encoded by the mdr1 gene,
MRP1, and MVP were detected by RT–PCR (Figure 6A) and
Western blots (Figure 6B). All the three cell lines lacked MGMT
mRNA and protein expression. Correspondingly, methylation
of the MGMT gene promoter was persistently detected in all three
cell lines (Figure 6C). Only very low amounts of mdr1 mRNA were
detectable by RT–PCR in BTL1 cells, which was even decreasing
from BTL2 to BTL3 (Figure 6B). In contrast, P-gp expression was
under the detection limit in all three sublines (data not shown).
Whereas MRP1 expression was constantly expressed in all
cell lines, MVP levels decreased continuously during disease
progression.
DISCUSSION
Multiple genetic alterations are generally found in solid tumours
and an increasing complexity of chromosomal aberrations is
typically associated with tumour progression (Albertson et al,
2003). This implies that chromosomal instability can act as a
driving force for tumorigenesis, leading to tumour cell immorta-
lisation and the acquisition of new subclones with features of
enhanced aggressiveness. Based on the assumption that gliomas
are clonal tumours (Bonneau and Longy, 2000), both shared
genetic changes as well as the appearance of additional alterations
during disease progression are expected to be found in glioblas-
tomas and their recurrences (Fujisawa et al, 1999; Saxena et al,
1999). Similarly, acquisition of therapy resistance is believed to
depend on the selection of subclones exhibiting activation of
the respective resistance mechanisms (Bredel, 2001). In this study,
we have analysed the dynamics of chromosomal instability and
chemosensitivity during glioblastoma progression using a unique
cell model comprising three cell lines derived from surgery
specimens of a long-term surviving glioblastoma patient. Cell
cultures were obtained from the primary tumour before therapy
and two consecutive recurrences resected during and 9 months
after termination of RT- and/or chemotherapy, respectively
(Table 1). The cell biological analyses of these cell models argue
against the hypothesis of a linear increase of tumour aggressive-
ness and therapy resistance during disease progression and reveal
that even late glioblastoma recurrences can represent relatively
inaggressive and highly chemosensitive tumour cell subclones.
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Figure 2 Cytogenetic analysis of the BTL glioblastoma cell model.
Representative CGH (A), FISH (B, C), and CDD banding (D–F) analyses
of the indicated cell lines are shown. Arrows in (A) indicate typical changes
for glioblastoma multiforme. For FISH analysis (B, C) a paint for whole
chromosome 7 (red) and a BAC clone for the EGFR locus (green) were
used. (D and E) show representative karyograms of the two subclones
detected in BTL1.
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Figure 3 In vitro growth dynamics of the BTL glioblastoma cell model.
Growth curves for the indicated cell lines were established as described in
Material and Methods. One of three experiments with comparable results
is shown.
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respective conclusions were also corroborated by the analysis of
paraffin-embedded material obtained from primary tumours
together with the corresponding recurrences of five additional
glioblastoma patients. Although in the three therapy-resistant
cases chromosomal aberrations increased during disease progres-
sion, two patients developed a recurrence with a less aberrant
genotype. Paralleling the BTL cell model, one of these patients
(GL5) responded to chemotherapy after relapse, whereas the other
patient (GL4) unfortunately refused further chemotherapy. All
three patients recurring with less aberrant genotypes showed a
remarkably long survival time. These data point towards general
differences in the dynamics of chromosomal instability and
chemosensitivity in short- and long-term surviving glioblastoma
patients. However, it has to be kept in mind that the current study
only involves one cell model and five additional glioblastoma
patients. Thus, further studies, including extended patient
numbers and, if possible, further cell models, are necessary to
confirm our observations.
Intratumoral heterogeneity of glioblastoma multiforme has been
mostly described with regard to histopathological features;
however, also the presence of genetically different cell clones
in glioblastoma at diagnosis has been occasionally reported
(Hulsebos et al, 2004). Correspondingly, cytogenetic analysis of
our primary tumor-derived BTL1 cell line demonstrated the
presence of at least two cell subclones with different chromosomal
aberrations. Although one of them exhibited strong chromosomal
instability and alterations associated with high aggressiveness,
CDD banding revealed the existence of a second, less rearranged
and nearly diploid subclone. Interestingly, these subclones
resembled in several aspects those cell lines established from the
first and second recurrence, namely BTL2 and BTL3 cells,
respectively.
In CGH analysis, the primary tumor- and the first recurrence-
derived cell lines BTL1 and BTL2 exhibited several alterations
characteristic of highly malignant gliomas, including loss of
chromosome 10q, with the PTEN and the MGMT gene locus on
10q23.3 and 10q26, respectively, loss of material from chromosome
9p, with the CDKN2A locus on 9p16, and gain of chromosome 7
resulting in amplifications at the epidermal growth factor receptor
(EGFR) locus on 7p12 (Inda et al, 2003). Interestingly, CGH and
FISH analyses revealed that BTL3, the second recurrence-derived
cell line, harboured neither any gains of chromosome 7 nor
additional EGFR copy numbers. Moreover, BTL3 cells demon-
strated reduced proliferative and migratory potential. This
suggests loss of several features of glioblastoma aggressiveness in
BTL3 probably based on lower EGFR-mediated signals (Aghi et al,
2005; Kang et al, 2005; Lamszus et al, 2005). Loss of chromosome 7
copy numbers was also observed in the recurrent tumour of GL5,
showing only a borderline gain of chromosome 7, whereas the
primary tumour displayed chromosome 7 amplification (data
not shown). Accordingly, EGFR amplification has been shown to
be a negative prognostic factor for overall survival of glioblastoma
patients and to correlate with shorter time to tumour progression
(Schlegel et al, 1994a,b; Zhu et al, 1996; Etienne et al, 1998).
Also gain of chromosome 7 together with loss of chromosome 10,
the most frequently found combined genetic alterations in
glioblastomas, are associated with poor prognosis and short
survival (Wiltshire et al, 2000; Ohgaki et al, 2004; Nigro et al,
2005).
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Figure 4 Migratory potential of the BTL glioblastoma cell model. Scratch assays were performed as described in Materials and Methods. (A)
Representative photomicrographs taken at the indicated time points are shown. (B) To determine the relative closure of the gap, photomicrographs as
shown in (A) were taken at different time points and measured using MetaMorph 6.1 software. The gaps’ widths immediately after wounding were arbitrarily
set as 1. At least three experiments with comparable results were performed.
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first recurrence is derived from the more aggressive subclone of
the primary tumour, which might be reflected by chromosomal
changes that are borderline in BTL1 but reach significance in BTL2
(losses in chromosomes 2, 6q, and 12q). The additional new
changes in BTL2 might be caused by DNA damage based on
proliferation under RT and chemotherapy. However, the enhanced
growth and migration potential in BTL2 as compared to BTL1
suggests that the observed differences might also reflect directed
malignant progression. In contrast, the surprisingly low aggres-
siveness of BTL3 cells together with a comparable subclone in
BTL1 cells suggest that dormant tumour cells from this or a
comparable BTL1 subclone could have evaded the two surgeries as
well as RT and chemotherapy. Correspondingly, Schmidt-Kittler
et al (2003) have reported an early dissemination of single breast
cancer cells with different chromosomal aberrations from the
primary tumour to the surrounding healthy tissue. Absence of
several alterations detected in the primary tumour suggested
dissemination not only from the most advanced clone but also
from pre-stages before immortalisation (Schmidt-Kittler et al,
2003). Alternatively, one might hypothesise that BTL3 is not
derived from BTL1 but represents a second unrelated metachro-
nous glioblastoma as has been reported before (Inda et al, 2003).
However, several shared chromosomal alterations both in BTL cell
lines as well as in the paired, paraffin-embedded tissue samples
analysed (data not shown) strongly suggest in all cases derivation
from a single founder clone that has developed to several
genetically different subclones during tumour progression.
The first recurrence, represented by BTL2 cells, developed after
ineffective chemotherapy and under RT. Consequently, one would
expect enhanced chemoresistance of this and all following
recurrences. Indeed, we detected moderately reduced sensitivity
after a 72h exposure of both BTL2 and BTL3 cells against the
nitrosourea BCNU in vitro. To our surprise, the sensitivity against
temozolomide, another alkylating agent, followed an inverse
pattern revealing a continuous increase in temozolomide sensitivity
from the primary tumour to the second recurrence. This was
based on enhanced cytotoxic activity of temozolomide in both
recurrence-derived cell lines with a particularly high cell death rate
in BTL3 cells. At longer exposure times and higher cell density,
BTL2 cells displayed the highest temozolomide-induced prolifera-
tion arrest, probably based on the more aggressive growth
behaviour of these cells. Correspondingly, the patient responded
to monotherapy with this agent after the first relapse. This might
implicate that temozolomide as a strong mutagen in the absence
of MGMT activity (Rabik et al, 2006) might have selected the less
aggressive BTL3 cell subclone by preferentially killing the highly
proliferative and not density-arrested BTL2 cell population. This is
especially notable as temozolomide treatment was recently shown
to significantly prolong overall survival of glioblastoma patients
(Stupp et al., 2005) and thus has largely replaced nitrosoureas in
the treatment of glioma (van den Bent et al, 2006).
With respect to temozolomide response, expression of the repair
enzyme MGMT was suggested as the major resistance factor
(Gerson, 2002) and lack of MGMT expression in gliomas is mainly
based on gene promoter methylation (Silber et al, 1998; Esteller
et al, 1999, 2000). Recently, promoter methylation was shown to
represent an independent prognostic factor in glioblastoma
patients (Hegi et al, 2005) and to be associated with enhanced
overall survival after treatment with RT/temozolomide (Hegi et al,
2004). In our cell model, a persistent methylation of the MGMT
gene promoter, even after application of temozolomide, has been
detected in all three BTL cell lines, resulting in a complete lack of
MGMT protein expression. Correspondingly, all BTL cell lines
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Figure 5 Antiproliferative and cytotoxic effects of temozolomide against
BTL cells. (A) The indicated BTL cell lines were exposed to increasing
temozolomide concentrations for 48h and the rate of DNA synthesis was
determined by
3H-thymidine incorporation. Data are given relatively to the
untreated controls set as 1. Means of two experiments in triplicates are
shown. (B) BTL cells were exposed for 5 days to the indicated
temozolomide concentrations and the percentage of apoptotic/dead cells
was determined by Hoechst 33258 and PI staining as described in Materials
and Methods. One representative example out of three experiments
delivering comparable results is shown.
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Figure 6 Expression of chemoresistance-related genes in BTL glioblas-
toma cells. mRNA (A) and protein (B) levels encoded by the indicated
chemoresistance genes were determined by RT–PCR and Western blot,
respectively. (C) Methylation of the MGMT promoter was detected by
methylation-specific PCR and a representative experiment is shown
(m¼methylated; u¼unmethylated). Protein extracts of the glioblastoma
cell lines GL80, GL54, and GL52 were used as positive controls for MGMT,
MVP, and MRP1, respectively.
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extent. Moreover, in the 72h exposure vitality assay an inverse
correlation of BCNU and temozolomide responsiveness was
surprisingly observed. However, it has to be mentioned that at
long BCNU exposure times (5 days), IC50 values for all three BTL
cell lines averaged out at about 60–80mM (data not shown)
whereas differences in case of temozolomide still were highly
significant. As all three BTL sublines did not express MGMT, other
resistance factors must underlie these observations. It has to be
kept in mind that BCNU and CCNU, as chloroethylating agents,
induce intra- and interstrand DNA crosslinks, whereas methylating
agents, like temozolomide, primarily lead to O
6-methylguanine
adducts (Aquilina et al, 1994). Several recent observations suggest
that resistance of glioblastomas to alkylating agents seems to
follow a more complex pattern than simple dependence on
MGMT levels. Thus, for example, the cellular p53 status and
consequently inducibility of p21 by alkylating agents (Bocangel
et al, 2002) as well as the base-excision repair capacity (Trivedi
et al, 2005) were shown to influence alkylating agent response.
Moreover, cells with mutated mismatch repair genes were
particularly resistant to temozolomide, but not to chloroethylating
agents (Gerson, 2002; Liu et al, 1996). In addition to repair
mechanisms, also signals regulating cell death and survival
pathways were implicated to regulate temozolomide response
(Bredel et al, 2006).
When comparing alkylating agents with several other chemo-
therapeutics, an increased response in the recurrence-derived BTL
cell lines was also observed in anthracyclines, whereas all cells were
persistently unresponsive to VP-16, CDDP, and bleomycin. High-
intrinsic chemoresistance of glioma cells has been reported by us
and other groups involving overexpression of known drug-
resistance proteins like P-gp, MRP1, and MVP (Berger et al,
2001; Bredel, 2001; Spiegl-Kreinecker et al, 2002). In our cell
model, we found very low levels of mdr1 mRNA without detectable
P-gp, persistent expression of MRP1, and reduction of MVP
expression especially in BTL3 cells. In a previous study, we
observed correlation between MVP expression of glioblastoma
cells and resistance to anthracyclines (Berger et al, 2001), which
suggests a contribution of MVP at least to doxorubicin hypersen-
sitivity of BTL3 cells. Additionally, EGFR-transmitted signals are
known to contribute to apoptosis resistance of glioblastoma cells
(Shinojima et al, 2003) leading, for example, to CDDP insensitivity
(Nagane et al, 1998). Moreover, response of xenografted gliomas to
different alkylating agents was attenuated by EGFR amplification
(Leuraud et al, 2004). Thus, the loss of EGFR amplification in BTL3
cells might also contribute to reduced chemoresistance.
From the clinical point of view, our data, although derived from
only one cell model and a very limited number of cases,
corroborate several clinical reports that have demonstrated activity
of temozolomide in patients with recurring astrocytic brain
tumours (for review see van den Bent et al, 2006). For example,
a recent study reported a 43% response rate for salvage therapy
with temozolomide for prior temozolomide responders at recur-
rence (Franceschi et al, 2005). In conclusion, we suggest that
application of temozolomide represents a feasible strategy for
glioblastoma treatment especially in patients with methylated
MGMT promoter even at repeated recurrence and following
chemo- and/or RT.
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